BACKGROUND: Morphologically malignant lymphocytes in the cerebrospinal fluid (CSF) are highly suggestive of central nervous system involvement by lymphoid malignancy. Although flow cytometry is increasingly used to detect a monoclonal B-cell population in the CSF, the significance of this finding in the absence of morphologically identifiable malignant cells is unknown. METHODS: We reviewed CSF flow cytometric results in 32 patients studied at a single institution over 5 years and identified patients who had monoclonal B-cells in the CSF. Clinical presentation and course were reviewed. RESULTS: Twelve patients had a monoclonal B-cell population in the CSF, but only three had clinical evidence of malignant CNS disease. Of the other nine patients, 4 had nonmalignant neurologic disease and five had a lymphoproliferative disorder: chronic lymphocytic leukemia (n = 4) and mantle cell lymphoma (n = 1). In patients who had chronic lymphocytic leukemia and mantle cell lymphoma, the monoclonal B-cell population was small and had an immunophenotype identical to that of circulating malignant B cells. None of these nine patients developed clinical evidence of malignant CNS involvement during follow-up. CONCLUSION: In patients who have indolent B-cell malignancies, the presence of monoclonal B cells in the CSF may not be diagnostic of clinically significant CNS involvement by a lymphoid malignancy. (c) 2004 Wiley-Liss, Inc.
BACKGROUND: Morphologically malignant lymphocytes in the cerebrospinal fluid (CSF) are highly suggestive of central nervous system involvement by lymphoid malignancy. Although flow cytometry is increasingly used to detect a monoclonal B-cell population in the CSF, the significance of this finding in the absence of morphologically identifiable malignant cells is unknown. METHODS: We reviewed CSF flow cytometric results in 32 patients studied at a single institution over 5 years and identified patients who had monoclonal B-cells in the CSF. Clinical presentation and course were reviewed. RESULTS: Twelve patients had a monoclonal B-cell population in the CSF, but only three had clinical evidence of malignant CNS disease. Of the other nine patients, 4 had nonmalignant neurologic disease and five had a lymphoproliferative disorder: chronic lymphocytic leukemia (n = 4) and mantle cell lymphoma (n = 1). In patients who had chronic lymphocytic leukemia and mantle cell lymphoma, the monoclonal B-cell population was small and had an immunophenotype identical to that of circulating malignant B cells. None of these nine patients developed clinical evidence of malignant CNS involvement during follow-up. CONCLUSION: In patients who have indolent B-cell malignancies, the presence of monoclonal B cells in the CSF may not be diagnostic of clinically significant CNS involvement by a lymphoid malignancy. (c) 2004 Wiley-Liss, Inc.
Authors: Marc Chamberlain; Larry Junck; Dieta Brandsma; Riccardo Soffietti; Roberta Rudà; Jeffrey Raizer; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Julie Walker; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Paolo Strati; Joon H Uhm; Timothy J Kaufmann; Chadi Nabhan; Sameer A Parikh; Curtis A Hanson; Kari G Chaffee; Timothy G Call; Tait D Shanafelt Journal: Haematologica Date: 2016-01-27 Impact factor: 9.941
Authors: Eva Cervilla Muñoz; Pablo Demelo Rodríguez; Alejandra García García; Javier Menarguez Palanca; Jorge Del Toro Cervera Journal: Clin Case Rep Date: 2017-10-06
Authors: Simone Lima de Souza; Fábio Santiago; Marilza de Moura Ribeiro-Carvalho; Adriano Arnóbio; Andréa Ribeiro Soares; Maria Helena Ornellas Journal: BMC Res Notes Date: 2014-09-13
Authors: Iole Cordone; Serena Masi; Diana Giannarelli; Alessia Pasquale; Laura Conti; Stefano Telera; Andrea Pace; Elena Papa; Mirella Marino; Paolo de Fabritiis; Andrea Mengarelli Journal: Front Oncol Date: 2021-06-03 Impact factor: 6.244